Grifols (GRF.MC) stock price, revenue, and financials

Grifols market cap is €10.9 b, and annual revenue was $5.34 b in FY 2020

€10.9 B

GRF.MC Mkt cap, 10-Nov-2021

$5.3 B

Grifols Revenue FY, 2020
Grifols Gross profit (FY, 2020)2.3 B
Grifols Gross profit margin (FY, 2020), %42.2%
Grifols Net income (FY, 2020)709 M
Grifols EBIT (FY, 2020)996.1 M
Grifols Cash, 31-Dec-2020579.6 M
Grifols EV13.6 B
Get notified regarding key financial metrics and revenue changes at GrifolsLearn more
Banner background

Grifols Revenue

Grifols revenue was $5.34 b in FY, 2020

Embed Graph

Grifols Revenue Breakdown

Embed Graph

Grifols revenue breakdown by business segment: 13.4% from Transfusional Medicine, 5.2% from Bio supplies, 78.3% from Bioscience and 3.1% from Other

Grifols revenue breakdown by geographic segment: 11.5% from European Union, 5.3% from Spain, 66.5% from USA and Canada and 16.7% from Rest of the world

Grifols Income Statement

Annual

EURFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

4.3b4.5b5.1b5.3b

Revenue growth, %

7%4%14%

Cost of goods sold

2.2b2.4b2.8b3.1b

Gross profit

2.2b2.0b2.3b2.3b

Gross profit Margin, %

50%46%46%42%

Sales and marketing expense

55.1m

R&D expense

288.3m240.7m276.0m294.2m

General and administrative expense

860.3m814.8m942.8m985.6m

Operating expense total

1.1b1.1b1.2b1.3b

EBIT

1.0b994.1m1.1b996.1m

EBIT margin, %

23%22%22%19%

Pre tax profit

695.7m725.8m817.1m878.6m

Income tax expense

34.4m131.4m168.5m169.6m

Net Income

661.3m594.4m648.6m709.0m

EPS

1.00.90.9

Half Year

EURH1, 2018H1, 2019H1, 2020

Revenue

2.1b2.4b2.7b

Cost of goods sold

1.1b1.3b1.6b

Gross profit

1.0b1.1b1.0b

Gross profit Margin, %

47%46%39%

R&D expense

112.2m132.6m142.1m

General and administrative expense

387.8m451.0m484.4m

Operating expense total

500.0m583.6m626.5m

EBIT

506.2m547.9m421.7m

EBIT margin, %

24%23%16%

Pre tax profit

397.3m368.3m327.1m

Income tax expense

79.4m73.7m65.5m

Net Income

317.9m294.6m261.7m

EPS

0.50.40.3

Grifols Balance Sheet

Annual

EURFY, 2017FY, 2018FY, 2019FY, 2020

Cash

886.5m1.0b742.0m579.6m

Accounts Receivable

286.2m269.2m369.8m383.2m

Inventories

1.6b1.9b2.3b2.0b

Current Assets

2.9b3.5b5.4b3.2b

PP&E

1.8b2.0b2.2b2.3b

Goodwill

4.6b5.2b5.5b5.3b

Total Assets

10.9b12.5b15.5b15.3b

Accounts Payable

423.1m561.9m581.9m

Short-term debt

33.5m28.2m228.6m

Current Liabilities

978.0m1.3b1.4b1.3b

Long-term debt

174.6m249.2m913.0m3.3b

Non-Current Liabilities

6.3b6.5b7.3b7.2b

Total Debt

208.1m277.4m1.1b3.3b

Total Liabilities

7.3b7.8b8.7b8.6b

Common Stock

119.6m119.6m119.6m

Additional Paid-in Capital

910.7m910.7m910.7m

Retained Earnings

662.7m596.6m625.1m

Total Equity

3.5b4.7b6.8b6.7b

Debt to Equity Ratio

0.1 x0.1 x0.2 x

Debt to Assets Ratio

0 x0 x0.1 x

Financial Leverage

3.1 x2.7 x2.3 x2.3 x

Grifols Cash Flow

Annual

EURFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

661.3m594.4m648.6m709.0m

Depreciation and Amortization

215.5m228.6m302.5m321.5m

Accounts Receivable

80.1m(13.1m)(99.4m)

Inventories

(165.5m)(231.7m)(323.7m)

Accounts Payable

22.3m135.3m(44.5m)

Cash From Operating Activities

841.7m737.4m568.9m1.1b

Purchases of PP&E

(251.5m)(232.0m)(310.4m)

Cash From Investing Activities

(2.2b)(781.9m)(548.8m)(858.1m)

Dividends Paid

(218.3m)(279.8m)(238.7m)

Cash From Financing Activities

1.4b152.5m(332.4m)(354.4m)

Net Change in Cash

(8.5m)147.3m(291.8m)

Interest Paid

207.1m225.1m236.2m

Income Taxes Paid

147.0m111.6m107.8m

Grifols Ratios

USDFY, 2017

Revenue/Employee

236.0k

Debt/Equity

0.1 x

Financial Leverage

3.1 x

P/E Ratio

23.6

Grifols Operating Metrics

FY, 2017Q1, 2018Q2, 2018Q3, 2018FY, 2018Q1, 2019Q2, 2019Q3, 2019FY, 2019Q1, 2020Q2, 2020Q3, 2020

Countries

100100100100100100100100100100100100

Plasma Collection Centers

190190225250256293295300310

Plasma Collection Centers (US)

190190190215197

Plasma Collection Centers (Europe)

353559

Plasma Obtained, liters

9.3 m12 m13.5 m

Hemoderivative Product Licenses

683694949

Diagnostic Product Licenses

2.32 k2.5 k3.04 k

Hospital Division Product Licenses

187186188

Bioscience R&D Projects (Discovery Phase)

141215

Bioscience R&D Projects (Preclinical Phase)

121219

Bioscience R&D Projects (Clinical Phase)

262821

Bioscience R&D Projects (Post Commercialization Studies Phase)

10910

Bioscience R&D Projects (Other)

181619

Patents and Patent Applications

2.7 k2.97 k3.18 k

Trademarks and Trademark Applications

3.15 k3.19 k3.38 k

Grifols Employee Rating

3.21503 votes
Culture & Values
3
Work/Life Balance
2.9
Senior Management
2.8
Salary & Benefits
3.3
Career Opportunities
3
Source